Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 68 citing articles:

Breakthroughs in Hepatocellular Carcinoma Therapies
Amit G. Singal, Masatoshi Kudo, Jordi Bruix
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2135-2149
Open Access | Times Cited: 79
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 321-338
Open Access | Times Cited: 67
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, et al.
Liver Cancer (2023) Vol. 13, Iss. 1, pp. 99-112
Open Access | Times Cited: 45
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Journal of Personalized Medicine (2022) Vol. 12, Iss. 11, pp. 1788-1788
Open Access | Times Cited: 62
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Masatoshi Kudo
Liver Cancer (2022) Vol. 11, Iss. 5, pp. 399-406
Open Access | Times Cited: 55
Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma
Xiao‐Dong Zhu, Cheng Huang, Ying‐Hao Shen, et al.
Annals of Surgical Oncology (2022) Vol. 30, Iss. 5, pp. 2782-2790
Open Access | Times Cited: 47
Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
Takeshi Hatanaka, Yutaka Yata, Atsushi Naganuma, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1798-1798
Open Access | Times Cited: 27
Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
Hui‐Chuan Sun, Xiao‐Dong Zhu
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 42
Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
Evgenia Kotsifa, Chrysovalantis Vergadis, Michail Vailas, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 3, pp. 436-436
Open Access | Times Cited: 36
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
Masatoshi Kudo
International Journal of Clinical Oncology (2022) Vol. 27, Iss. 7, pp. 1110-1119
Open Access | Times Cited: 32
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study
Masatoshi Kudo, Richard S. Finn, Peter R. Galle, et al.
Liver Cancer (2022) Vol. 12, Iss. 3, pp. 238-250
Open Access | Times Cited: 29
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab
Tatsuya Kikuchi, Yasuto Takeuchi, Kazuhiro Nouso, et al.
Liver International (2024) Vol. 44, Iss. 6, pp. 1456-1463
Open Access | Times Cited: 7
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Masatoshi Kudo
Liver Cancer (2023) Vol. 12, Iss. 1, pp. 1-6
Open Access | Times Cited: 13
Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning
Wendao Liu, Ran Wei, Junwei Chen, et al.
European Radiology (2024) Vol. 34, Iss. 8, pp. 5094-5107
Open Access | Times Cited: 5
Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study
Jiayi Wu, Jiayi Wu, Yang-Kai Fu, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 5, pp. 3073-3083
Closed Access | Times Cited: 5
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 242-251
Open Access | Times Cited: 12
Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy
Masatoshi Kudo
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 289-296
Open Access | Times Cited: 12
Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update
Masatoshi Kudo
Liver Cancer (2023) Vol. 12, Iss. 2, pp. 95-102
Open Access | Times Cited: 11
Advances in Immunotherapy for Hepatocellular Carcinoma
Satoru Hagiwara, Naoshi Nishida, Masatoshi Kudo
Cancers (2023) Vol. 15, Iss. 7, pp. 2070-2070
Open Access | Times Cited: 11
Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma
Nobuaki Ishihara, Shohei Komatsu, Keitaro Sofue, et al.
Hepatology Research (2024) Vol. 54, Iss. 8, pp. 773-780
Closed Access | Times Cited: 4
A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial
Zhimei Huang, Xue Han, Jian Wang, et al.
Liver Cancer (2024) Vol. 13, Iss. 4, pp. 438-450
Open Access | Times Cited: 4
Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study
Xiaoshi Zhang, Xiaodong Zhu, Jian‐Hong Zhong, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Validation of an albumin-indocyanine green-based China liver cancer staging system to evaluating resectable hepatocellular carcinoma patients and comparison with the Child-Pugh-based China liver cancer staging system
M S Chen, Chao Ren, MengXia Wang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study
Tomoko Aoki, Masatoshi Kudo, Naoshi Nishida, et al.
Journal of Gastroenterology (2025)
Open Access
Efficacy of transarterial chemoembolization combined with radiofrequency ablation in the treatment of liver metastases from colorectal cancer.
J. Yin, Yongli Zhao, Junping Yin, et al.
PubMed (2025)
Closed Access
Page 1 - Next Page

Scroll to top